NCAM-1

NCAM-1 詳細

英語名Neural cell adhesion molecule 1市販薬剤の数0
治験薬の数6ターゲットの別称Neural cell adhesion molecule 1,CD56,NCAM1,NCAM,Neural Cell Adhesion Molecule, NCAM,CD56 Antigen,N-CAM-1,MSK39,NCAM-1,Antigen Recognized By Monoclonal Antibody 5.1H11
研究&開発段階Phase 2 Clinical
英語名Neural cell adhesion molecule 1
ターゲットの別称Neural cell adhesion molecule 1,CD56,NCAM1,NCAM,Neural Cell Adhesion Molecule, NCAM,CD56 Antigen,N-CAM-1,MSK39,NCAM-1,Antigen Recognized By Monoclonal Antibody 5.1H11
市販薬剤の数0
治験薬の数6
研究&開発段階Phase 2 Clinical

NCAM-1 製品リスト

  • 属性

    Protein (9)

  • 製品ライブラリ

    オンライン (9)

  • Human (8)Mouse (1)

  • タグ

    His Tag (5)Fc Tag (2)His Tag & Avi Tag (1)Llama IgG Fc Tag (1)

  • マーカー

    Unconjugated (4)Biotin-labeled (1)FITC Labeled (2)AF488 Labeled (1)AF647 Labeled (1)

NCAM-1バックグランド

NCAM1 belongs to the immunoglobulin superfamily of adhesion molecules. A wide range of alternatively spliced NCAM1 messenger RNAs (mRNAs) has been described to date, but only the 120-, 140-, and 180- kDa isoforms are commonly expressed. NCAM1 plays an important role in the regulation of neurogenesis, neurite outgrowth, proliferation, and cell migration, however, its function in hematopoiesis, including NK cells, is poorly understood. NCAM1 signaling is mediated either by homophilic or heterophilic interactions with fibroblast growth factor receptor (FGFR), L1-CAM, N-cadherin and other components of the extracellular matrix. Upon activation, NCAM1 triggers a variety of signaling cascades including FYN–focal adhesion kinase (FAK), MAPK, and phosphatidylinositol 3-kinase (PI3K) pathways.

NCAM-1分子の別称

CD56,MSK39,NCAM1,N-CAM-1

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Lorvotuzumab mertansineBB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1Phase 2 ClinicalImmunogen IncCarcinoma, Merkel Cell; Leukemia; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pulmonary Blastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Small Cell Lung Carcinoma; Wilms Tumor
詳細
EB-DART-NK01EB-DART-NK01Phase 2 ClinicalBeijing BiotechSmall Cell Lung Carcinoma
詳細
CUBT-906CUBT-906Phase 2 ClinicalCurative Biotechnology IncGlioblastoma
詳細
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR GD2/CD56Phase 2 ClinicalShenzhen Geno-Immune Medical InstituteNeoplasms
詳細
IN-B015IN-B-015; IN-B00004Phase 1 ClinicalHK inno.N CorporationNeoplasms
詳細
DXC-006DXC-006; DAC-006Phase 1 ClinicalHangzhou Dac Biotech Company LtdHematologic Neoplasms; Lung Neoplasms; Solid tumours
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8